Vestor Capital LLC reduced its stake in The Clorox Company (NYSE:CLX – Free Report) by 97.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 850 shares of the company’s stock after selling 27,084 shares during the period. Vestor Capital LLC’s holdings in Clorox were worth $88,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the stock. Haverford Trust Co lifted its position in Clorox by 2.8% in the 4th quarter. Haverford Trust Co now owns 3,070 shares of the company’s stock worth $310,000 after buying an additional 84 shares during the last quarter. Field & Main Bank grew its position in Clorox by 3.3% during the fourth quarter. Field & Main Bank now owns 3,100 shares of the company’s stock valued at $313,000 after acquiring an additional 100 shares during the last quarter. Golden State Wealth Management LLC grew its position in Clorox by 28.2% during the fourth quarter. Golden State Wealth Management LLC now owns 454 shares of the company’s stock valued at $46,000 after acquiring an additional 100 shares during the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of Clorox by 1.8% during the first quarter. Kestra Private Wealth Services LLC now owns 5,957 shares of the company’s stock worth $617,000 after acquiring an additional 104 shares in the last quarter. Finally, Johnson Financial Group Inc. lifted its holdings in shares of Clorox by 3.1% in the 3rd quarter. Johnson Financial Group Inc. now owns 3,659 shares of the company’s stock worth $451,000 after acquiring an additional 109 shares during the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on CLX. Morgan Stanley cut their price objective on shares of Clorox from $110.00 to $97.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Royal Bank Of Canada decreased their target price on shares of Clorox from $132.00 to $127.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 9th. BNP Paribas Exane lowered their price target on shares of Clorox from $97.00 to $95.00 and set a “neutral” rating for the company in a research note on Monday, July 20th. Wells Fargo & Company cut their price target on shares of Clorox from $100.00 to $95.00 and set an “equal weight” rating for the company in a research report on Monday, May 18th. Finally, Barclays raised their price objective on Clorox from $85.00 to $86.00 and gave the company an “underweight” rating in a research note on Tuesday, July 21st. Twelve equities research analysts have rated the stock with a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $101.00.
Clorox Stock Performance
NYSE:CLX opened at $95.66 on Friday. The company has a debt-to-equity ratio of 27.03, a quick ratio of 0.65 and a current ratio of 0.84. The Clorox Company has a fifty-two week low of $84.70 and a fifty-two week high of $128.90. The firm has a market cap of $11.57 billion, a PE ratio of 15.53 and a beta of 0.54. The business has a 50 day moving average price of $95.51 and a 200-day moving average price of $103.67.
Clorox (NYSE:CLX – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $1.64 EPS for the quarter, topping the consensus estimate of $1.55 by $0.09. Clorox had a net margin of 11.18% and a return on equity of 443.64%. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the firm earned $1.45 earnings per share. The firm’s revenue for the quarter was up .1% on a year-over-year basis. Equities research analysts predict that The Clorox Company will post 5.52 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Pierre R. Breber purchased 5,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was acquired at an average price of $85.82 per share, with a total value of $429,100.00. Following the transaction, the director directly owned 18,000 shares of the company’s stock, valued at approximately $1,544,760. This represents a 38.46% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.63% of the stock is owned by insiders.
Clorox Company Profile
The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.
Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.
Read More
- Five stocks we like better than Clorox
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.
